复方夏天无联合甲氨喋呤治疗类风湿性关节炎的短期临床观察

Short-term clinical observation on compound Xiatianwu combined with methotrexate in treating rheumatoid arthritis

目的:观察复方夏天无联合甲氨蝶呤治疗类风湿性关节炎的短期临床疗效。方法:将104例类风湿性关节炎患者随机分为联合治疗组64例及对照组40例,联合治疗组予复方夏天无联合甲氨喋呤治疗,对照组仅加用甲氨喋呤。比较治疗前后ACR20,ACR50,ACR70及实验室指标(抗环瓜氨酸多肽抗体、类风湿因子、血沉、超敏C反应蛋白),并观察2组患者不良反应。结果:治疗3个月后,联合治疗组的ACR20改善率为59.4%,高于对照组的35%,差异有统计学意义(P<0.05);ACR50改善率为32.8%,也高于对照组17.5%,差异具有统计学意义(P<0.05);治疗3个月后,2组患者抗环瓜氨酸多肽抗体、类风湿因子、血沉、超敏C反应蛋白均较治疗前明显好转,有统计学意义(P<0.05)。联合治疗组血沉、超敏C反应蛋白比甲氨喋呤组改善更为显著(P<0.05)。联合治疗组不良反应事件发生率明显低于甲氨喋呤组(P<0.05)。结论:复方夏天无联合甲氨喋呤治疗短期内能有效改善患者临床症状及实验室指标,并具有更高的用药安全性。

Objective： To observe the short-term clinical efficacy of compound Xiatianwu combined with methotrexate （MTX） in treating rheumatoid arthritis. Method： One hundred and four patients with rheumatoid arthritis were randomly divided into two groups： 64 cases in the combined treatment group who was treated with compound Xiatianwu combined with MTX, and the remaining 40 cases in the control group which was only treated with MTX. The changes in ACR20, ACR50, ACR70 and laboratory indexes inclu- ding anti-cyclic citrulline polypeptide, rheumatoid factor, erythrocyte sedimentation rate, high sensitivity creative protein were com- pared before and after treatment. Adverse reactions in the two groups were observed as well. Result： After being treated for 3 months, the ACR20 improvement rate reached 59.4% in the combined treatment group, higher than 35% in the control group, with significant statistical difference （P 〈 0.05） ; The ACR.50 improvement rate reached 32. 8% the treated group, also higher than 17. 5% in the con- trol group, with significant statistical difference （P 〈 0. 05）. After treatment for three months, both groups showed remarkable im- provement in anti-cyclic citrulline polypeptide, rheumatoid factor, erythrocyte sedimentation rate and high sensitivity creative protein compared with that before treatment, demonstrating statistical significance （P 〈 0. 05）. The combined treatment group displayed more significant improvement in erythrocyte sedimentation rate and high sensitivity creative protein as well as much less adverse reactions than the MTX group. Conclusion： Compound Xiatianwu combined with MTX can effectively improve clinical symptoms of RA patients and laboratory indexes, and shows higher medication safety.